What do systematic reviews say?

Nanofiltered C1 esterase inhibitor vs placebo or active control

The review found no eligible studies for this question.

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Nanofiltered C1 esterase inhibitor vs placebo or active control

The review found no eligible studies for this question.

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Nanofiltered C1 esterase inhibitor vs placebo or active control

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 16 participants
  Very low

Nanofiltered C1 esterase inhibitor vs placebo or active control

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 16 participants
  Very low

Nanofiltered C1 esterase inhibitor vs placebo or active control

The review found no eligible studies for this question.

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Plasma‐derived C1 esterase inhibitor vs placebo or active control

The review found no eligible studies for this question.

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Plasma‐derived C1 esterase inhibitor vs placebo or active control

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 71 participants
  Low

Plasma‐derived C1 esterase inhibitor vs placebo or active control

The review found no eligible studies for this question.

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Plasma‐derived C1 esterase inhibitor vs placebo or active control

It is very uncertain whether plasma‐derived C1 esterase inhibitor changes serious adverse events (during compared with placebo or active control (very low certainty).

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  RR 0.54 [0.09, 3.1]
  1 study · 71 participants
  Very low

Plasma‐derived C1 esterase inhibitor vs placebo or active control

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 31 participants
  Low

Plasma‐derived C1 esterase inhibitor vs placebo or active control

The review found no eligible studies for this question.

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Plasma‐derived C1 esterase inhibitor vs placebo or active control

Plasma‐derived C1 esterase inhibitor showed no clear difference in adverse events(during compared with placebo or active control (low certainty).

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  RR 1.05 [0.78, 1.42]
  1 study · 71 participants
  Low

Recombinant human C1 esterase inhibitor vs placebo or active control

The review found no eligible studies for this question.

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Recombinant human C1 esterase inhibitor vs placebo or active control

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 32 participants
  Very low

Recombinant human C1 esterase inhibitor vs placebo or active control

The review found no eligible studies for this question.

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Recombinant human C1 esterase inhibitor vs placebo or active control

It is very uncertain whether recombinant human C1 esterase inhibitor changes serious adverse events (during compared with placebo or active control (very low certainty).

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  RR 1.5 [0.06, 34.66]
  1 study · 29 participants
  Very low

Recombinant human C1 esterase inhibitor vs placebo or active control

The review found no eligible studies for this question.

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Recombinant human C1 esterase inhibitor vs placebo or active control

The review found no eligible studies for this question.

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Recombinant human C1 esterase inhibitor vs placebo or active control

Recombinant human C1 esterase inhibitor showed no clear difference in adverse events(during compared with placebo or active control (low certainty).

• Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
  RR 1.39 [0.71, 2.7]
  1 study · 29 participants
  Low

Phosphodiesterase 4 inhibitors vs placebo

• Phosphodiesterase‐4 inhibitors for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes only
  no estimate extracted
  29 studies · 20815 participants
  Moderate